SEC Form 4 · accession 0001127602-15-029479

HAEMONETICS CORP · HAE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, Global Manufacturing

Period of report

Oct 20, 2015

Accepted (ET)

Oct 23, 2015 · 2:57 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000313143

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Oct 20, 2015	A	4,222	$0.01	A	4,222	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Performance Shares^F2	$0.00	Oct 20, 2015	A	10,250	A	Mar 31, 2017	Dec 31, 2017	Common Stock	10,250	10,250	D
Non-qualified Stock Option (Right to Buy)^F3	$31.97	Oct 20, 2015	A	43,310	A	Oct 20, 2016	Oct 20, 2022	Common Stock	43,310	43,310	D

F1Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.
F2Market Stock Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Company's stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).
F3Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.